Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunitybio Inc (IBRX)
:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.28 - $10.53
Previous CloseN/A
Volume1.20M
Average Volume (3M)6.52M
Market Cap
$2.50B
Enterprise Value$3.49B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.34
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding730,164,600
10 Day Avg. Volume6,255,627
30 Day Avg. Volume6,518,602
Standard Deviation0.32
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)345.94
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.60K
Enterprise Value/Ebitda-8.28
Forecast
1Y Price Target
$6.00Price Target Upside75.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
ImmunityBio News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsANKTIVA has demonstrated early but compelling data in checkpoint relapsed NSCLC with an observed mOS of 14.1 months, which is beneficial relative to the ~10 months mOS seen with docetaxel.
Strategic PartnershipsImmunityBio struck an exclusive global arrangement with the Serum Institute of India for the global supply of BCG across cancer types, including a next-generation recombinant BCG.
Bears Say
Market ChallengesThe confirmatory and global Ph 3 ResQ201A-NSCLC study will evaluate ANKTIVA plus tislelizumab and docetaxel vs. docetaxel randomized 2:1 in advanced/metastatic NSCLC post checkpoint inhibitor therapy.
---
Ownership Overview
89.57% Insiders
3.03% Mutual Funds
2.58% Other Institutional Investors
0.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IBRX FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was $2.28 and its highest was $10.53 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is $2.50B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is May 08, 2025 which is in 74 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on Nov 12, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.038.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 730,164,600 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went down -9.174%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in IBRX
---
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (75.44% Upside)
$6.00 (75.44% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $230.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.92%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-15.69%
Trailing 12-Months
Company Description
Immunitybio Inc
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
---
IBRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(75.44% Upside)
Technical Analysis
Best Analysts Covering IBRX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
+23.34%
reiterated a buy rating 6 months ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +23.34% per trade.
---